Erlotinib (Tarceva®®) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro

Author： Hinerman Ray   Gao Weiyi   Ramadan Hassan H   Cunningham Cynthia   Zhang Peilin  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.1, Iss.1, 2004-09, pp. : 67-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral cavity and oropharyngeal squamous cell carcinoma—an update

By  

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 65, Iss. 5, 2015-09 ,pp. : 401-421

John Wiley & Sons Inc

Access to resources Recommend Favorite

A population‐based analysis of verrucous carcinoma of the oral cavity

By  

THE LARYNGOSCOPE, Vol. 128, Iss. 2, 2018-02 ,pp. : 393-397

John Wiley & Sons Inc

Access to resources Recommend Favorite

Susceptibility of porcine peripheral blood to ionizing radiation in vivo and in vitro experiments.

By Zarybnicka L.   Sinkorova Z.  

Radioprotection, Vol. 43, Iss. 5, 2008-09 ,pp. : 010-010

Edp Sciences

Access to resources Recommend Favorite

Algorithm to predict postoperative complications in oropharyngeal and oral cavity carcinoma

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 4, 2015-04 ,pp. : 548-556

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 214-221

John Wiley & Sons Inc

Access to resources Recommend Favorite